Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Thrombosis and Thrombolysis
Published in: Journal of Thrombosis and Thrombolysis 3/2018

01-10-2018

Non-vitamin K antagonist oral anticoagulants for the treatment of intracardiac thrombosis

Authors: Eiman Ghaffarpasand, Maneli D. Tehrani, Jolanta Marszalek, Gerald Chi

Published in: Journal of Thrombosis and Thrombolysis | Issue 3/2018

Login to get access

Abstract

Intracardiac thrombus most commonly develops in the left atrial appendage (LAA) and left ventricle (LV) in the setting of atrial fibrillation (AF) and post-myocardial fibrillation (MI), respectively. Current guidelines recommend that patients with post-MI LV or LAA thrombus should be treated with vitamin K antagonist (VKA). However, the use of VKA may be limited by bleeding complications, interactions with various food and drugs, and a narrow therapeutic window requiring frequent monitoring. Thus, non-VKA oral anticoagulants (NOACs) have been attempted as an off-label use for the treatment of intracardiac thrombosis in light of their favorable pharmacologic profile. Until now, therapeutic effect of NOACs on intracardiac thrombosis has not been formally studied in large randomized controlled trials. This article aims to systematically review the literature regarding efficacy and safety outcome of NOACs in the management of intracardiac thrombus. Considering the high rate of complete thrombus resolution and low rate of thromboembolic or hemorrhagic complications, preliminary evidence from case series and reports indicate that NOACs (including factor Xa inhibitors and direct thrombin inhibitors) may be a safe and effective therapeutic option for intracardiac thrombosis, particularly in cases resistant to VKA therapy.
Appendix
Available only for authorised users
Literature
1.
Virchow RLK (1856) Gesammelte Abhandlungen zur Wissenschaftlichen Medicin. Meidinger Sohn & Co., Frankfurt
2.
Watson T, Shantsila E, Lip GY (2009) Mechanisms of thrombogenesis in atrial fibrillation: Virchow’s triad revisited. Lancet 373:155–166CrossRefPubMed
3.
4.
Egolum UO, Stover DG, Anthony R, Wasserman AM, Lenihan D, Damp JB (2013) Intracardiac thrombus: diagnosis, complications and management. Am J Med Sci 345:391–395CrossRefPubMed
5.
Lee JM, Park JJ, Jung HW, Cho YS, Oh IY, Yoon CH et al (2013) Left ventricular thrombus and subsequent thromboembolism, comparison of anticoagulation, surgical removal, and antiplatelet agents. J Atheroscler Thromb 20:73–93CrossRefPubMed
6.
Osherov AB, Borovik-Raz M, Aronson D, Agmon Y, Kapeliovich M, Kerner A et al (2009) Incidence of early left ventricular thrombus after acute anterior wall myocardial infarction in the primary coronary intervention era. Am Heart J 157:1074–1080CrossRefPubMed
7.
Keeley EC, Hillis LD (1996) Left ventricular mural thrombus after acute myocardial infarction. Clin Cardiol 19:83–86CrossRefPubMed
8.
Driesman A, Hyder O, Lang C, Stockwell P, Poppas A, Abbott JD (2015) Incidence and predictors of left ventricular thrombus after primary percutaneous coronary intervention for anterior st-segment elevation myocardial infarction. Clin Cardiol 38:590–597CrossRefPubMedPubMedCentral
9.
10.
Ogren M, Bergqvist D, Eriksson H, Lindblad B, Sternby NH (2005) Prevalence and risk of pulmonary embolism in patients with intracardiac thrombosis: a population-based study of 23 796 consecutive autopsies. Eur Heart J 26:1108–1114CrossRefPubMed
11.
Brodmann M, Stark G, Pabst E, Lueger A, Pilger E (2000) Pulmonary embolism and intracardiac thrombi-individual therapeutic procedures. Vasc Med 5:27–31PubMed
12.
Bogiatzi C, Hackam DG, McLeod AI, Spence JD (2014) Secular trends in ischemic stroke subtypes and stroke risk factors. Stroke 45:3208–3213CrossRefPubMed
13.
Lin H-J, Wolf PA, Kelly-Hayes M, Beiser AS, Kase CS, Benjamin EJ et al (1996) Stroke severity in atrial fibrillation: the Framingham Study. Stroke 27:1760–1764CrossRefPubMed
14.
Sen S, Laowatana S, Lima J, Oppenheimer SM (2004) Risk factors for intracardiac thrombus in patients with recent ischaemic cerebrovascular events. J Neurol Neurosurg Psychiatry 75:1421–1425CrossRefPubMedPubMedCentral
15.
16.
17.
European Heart Rhythm Association (EHRA), European Association for Cardio-Thoracic Surgery (EACTS), Camm AJ, Kirchhof P, Lip GY, Schotten U et al (2010) Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J 31:2369–2429CrossRef
18.
January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr et al (2014) 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 130:e199–e267CrossRefPubMedPubMedCentral
19.
Orenes-Pinero E, Esteve-Pastor MA, Valdes M, Lip GYH, Marin F (2017) Efficacy of non-vitamin-K antagonist oral anticoagulants for intracardiac thrombi resolution in nonvalvular atrial fibrillation. Drug Discov Today 22:1565–1571CrossRefPubMed
20.
Hammerstingl CSR, Nickenig G, Weber M, Lambers M (2015) Direct acting oral anticoagulants are more effective than vitamin-K-antagonists for the resolution of established left atrial thrombi in patients with atrial fibrillation. Eur Heart J 65:849–1187
21.
Hao L, Zhong JQ, Zhang W, Rong B, Xie F, Wang JT et al (2015) Uninterrupted dabigatran versus warfarin in the treatment of intracardiac thrombus in patients with non-valvular atrial fibrillation. Int J Cardiol 190:63–66CrossRefPubMed
22.
Lip GY, Hammerstingl C, Marin F, Cappato R, Meng IL, Kirsch B et al (2016) Left atrial thrombus resolution in atrial fibrillation or flutter: results of a prospective study with rivaroxaban (X-TRA) and a retrospective observational registry providing baseline data (CLOT-AF). Am Heart J 178:126–134CrossRefPubMed
23.
Smetana KS, Dunne J, Parrott K, Davis GA, Collier ACS, Covell M et al (2017) Oral factor Xa inhibitors for the treatment of left ventricular thrombus: a case series. J Thromb Thrombolysis 44:519–524CrossRefPubMed
24.
Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH et al (2012) 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 33:2719–2747CrossRefPubMed
25.
January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr et al (2014) 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 64:e1-76CrossRefPubMed
26.
Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ et al (2013) Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 369:1206–1214CrossRefPubMed
27.
Andreas M, Moayedifar R, Wieselthaler G, Wolzt M, Riebandt J, Haberl T et al (2017) Increased thromboembolic events with dabigatran compared with vitamin K antagonism in left ventricular assist device PatientsCLINICAL PERSPECTIVE: a randomized controlled pilot trial. Circ: Heart Fail 10:e003709
28.
Holy EW, Beer H-J (2013) Update on the status of new oral anticoagulants for stroke prevention in patients with atrial fibrillation. Cardiovasc Med 16:103–114CrossRef
29.
Hoffman R, Brenner B (2012) The promise of novel direct oral anticoagulants. Best Pract Res Clin Haematol 25:351–360CrossRefPubMed
30.
Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H et al (2016) Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 149:315–352CrossRefPubMed
31.
Ferner M, Wachtlin D, Konrad T, Deuster O, Meinertz T, von Bardeleben S et al (2016) Rationale and design of the RE-LATED AF–AFNET 7 trial: REsolution of Left atrial-Appendage Thrombus–Effects of Dabigatran in patients with Atrial Fibrillation. Clin Res Cardiol 105:29–36CrossRefPubMed
32.
Kawakami T, Kobayakawa H, Ohno H, Tanaka N, Ishihara H (2013) Resolution of left atrial appendage thrombus with apixaban. Thrombo J 11:26CrossRef
33.
34.
Khan A (2014) Angioedema: an uncommon but potentially life-threatening drug reaction of apixaban. International Academy of Cardiology Annual Scientific Sessions 2014 19th World Congress on Heart Disease. Boston, pp 1–527
35.
Jacobs B, Willems R, Garweg C (2015) Why it is important to use the correct dose of the non-vitamin K oral anticoagulants. Eur Heart J Cardiovasc Imaging 16:461CrossRefPubMed
36.
Freixa X, Scalone G, Martin-Yuste V, Vidal B (2015) Large protruding thrombus over left atrial appendage occlusion device successfully treated with apixaban. Eur Heart J 36:1427CrossRefPubMed
37.
38.
Ohyagi M, Nakamura K, Watanabe M, Fujigasaki H (2015) Embolic stroke during apixaban therapy for left atrial appendage thrombus. J Stroke Cerebrovasc Dis Off J Natl Stroke Assoc 24:e101–e102CrossRef
39.
Vaquerizo B, Sami M (2015) Left atrial appendage thrombus resolution with reduced dose apixaban. J Atrial Fibrillation 8:1182
40.
Yanikoglu A, Altintas MS, Ekinozu I (2015) Dissolution of an apical thrombus by apixaban in a patient with old anteroseptal myocardial infarction. Anatol J Cardiol 15:671–672CrossRefPubMed
41.
Bolayır HA, Güneş H, Şahin Ö, Akaslan D, Kıvrak T (2016) Complete resolution of huge left ventricular thrombus with apixaban treatment. Int J Cardiovasc Acad 2:160–161CrossRef
42.
Eftekhari A, Damgaard D, Grove EL (2016) Fatal stroke following treatment with apixaban in a patient with atrial fibrillation and left atrial appendage thrombus. Int J Cardiol 214:131–132CrossRefPubMed
43.
González-Matos CE, Cózar-León R, Bastos-Amador P, Díaz-Infante E (2016) Special program and abstract issue of the 12th Annual Congress of the European Cardiac Arrhythmia Society (ECAS). J Interv Cardiac Electrophysiol: Int J Arrhythm Pacing 45:233–333CrossRef
44.
Kaya A, Hayiroglu MI, Keskin M, Tekkesin AI, Alper AT (2016) Resolution of left ventricular thrombus with apixaban in a patient with hypertrophic cardiomyopathy. Turk Kardiyoloji Dernegi arsivi: Turk Kardiyoloji Derneginin yayin organidir 44:335–337
45.
Kemmner S, Lesevic H, Reents T, Schunkert H, Burgdorf C (2016) Right ventricular thrombus formation in a patient with arrhythmogenic right ventricular dysplasia following radiofrequency ablation. Clini Case Rep 4:554–557CrossRef
46.
Lee SH, Han S (2016) Series with complete resolution of left atrial appendage thrombi with apixaban in elderly patients. Kor J Intern Med 31:396–398CrossRef
47.
Mano Y, Koide K, Sukegawa H, Kodaira M, Ohki T (2016) Successful resolution of a left ventricular thrombus with apixaban treatment following acute myocardial infarction. Heart Vessels 31:118–123CrossRefPubMed
48.
Miwa Y, Minamishima T, Sato T, Sakata K, Yoshino H, Soejima K (2016) Resolution of a warfarin and dabigatran-resistant left atrial appendage thrombus with apixaban. J Arrhythm 32:233–235CrossRefPubMedPubMedCentral
49.
50.
Shamim S, Magalski A, Chhatriwalla AK, Allen KB, Huber KC, Main ML (2017) Transesophageal echocardiographic diagnosis of a WATCHMAN left atrial appendage closure device thrombus 10 years following implantation. Echocardiography 34:128–130CrossRefPubMed
51.
Valero E, Santas E, Nunez J (2016) Thrombolytic action of apixaban on intra-atrial thrombus developed after previous treatment with warfarin: a case report. Med Princ Pract 25:491–493CrossRef
52.
Yildirim E, Kalkan K, Ipek E, Demirelli S, Ermiş E (2016) Successful resolution of left ventricular thrombus with apixaban treatment. Int J Cardiovasc Acad 2:57–58CrossRef
53.
Abubakar H, Shokr M, Subahi A, Rashed A (2017) Reduced dose apixaban resolving dual cardiac chamber thrombi in a patient with ischaemic cardiomyopathy in sinus rhythm. BMJ Case Rep 2017:bcr-2017
54.
Berry A, Brancheau D, Zughaib M (2017) Rapid resolution of left ventricular thrombus with apixaban therapy. SAGE Open Med Case Rep 5:2050313X17745211PubMedPubMedCentral
55.
Koyama T, Otsuka Y, Kawahara M, Imoto Y, Nakamura K, Kodama S et al (2017) A left atrial appendage thrombus that developed during prophylactic low-dose dabigatran treatment resolved after switching to apixaban. Clin Case Rep 5:711–713CrossRefPubMedPubMedCentral
56.
Okada T, Takaekou Y, Idei N, Ohashi N, Kaseda S (2017) Resolution of left atrial appendage thrombus with apixaban in a patient with heart failure. Intern Med 56:2891–2894CrossRefPubMedPubMedCentral
57.
Scognamiglio G, Barracano R, Sarubbi B (2017) Resolution of intracardiac thrombus with novel oral anticoagulants in an adult patient with complex CHD. Cardiol Young 27:1616–1617CrossRefPubMed
58.
Hammerstingl C, Potzsch B, Nickenig G (2013) Resolution of giant left atrial appendage thrombus with rivaroxaban. Thromb Haemost 109:583–584CrossRefPubMed
59.
Takasugi J, Yamagami H, Okata T, Toyoda K, Nagatsuka K (2013) Dissolution of the left atrial appendage thrombus with rivaroxaban therapy. Cerebrovasc Dis 36:322–323CrossRefPubMed
60.
Hsieh H-C, Tsai Y-S, Chen C-H (2014) Abstracts of the Annual Conference of the Asia Pacific Stroke Organization (APSO), September 12–14, 2014, Taipei, Taiwan. Cerebrovasc Dis 38(Suppl 1):1–114
61.
Kato T, Yasaka M, Yabuki T, Adachi T, Toyoda S, Inoue T (2014) Two-week administration of rivaroxaban resolved left atrial thrombus. J Cardiol Cases 10:238–240CrossRef
62.
Nakasuka K, Ito S, Noda T, Hasuo T, Sekimoto S, Ohmori H et al (2014) Resolution of left ventricular thrombus secondary to tachycardia-induced heart failure with rivaroxaban. Case Rep Med 2014:814524CrossRefPubMedPubMedCentral
63.
Okata T, Toyoda K, Okamoto A, Miyata T, Takasugi J, Koga M et al (2014) Abstract T P348: successful resolution of the cardiac thrombus using novel oral anticoagulants. Stroke 45:ATP348-ATP
64.
Padilla Perez M, Salas Bravo D, Garcelan Trigo JA, Vazquez Ruiz de Castroviejo E, Torres Llergo J, Lozano Cabezas C et al (2014) Resolution of left ventricular thrombus by rivaroxaban. Fut Cardiol 10:333–336CrossRef
65.
Parato VM, Scarano M, Labanti B (2014) Thrombophilia-related complications in the treatment of a left atrial appendage thrombus: a case report. J Cardiovasc Echography 24:64–55CrossRef
66.
Saito S, Tomita H, Kimura Y, Shiroto H, Hagii J, Metoki N et al (2014) Reduced smoke-like echo and resolved thrombus in the left atrium with rivaroxaban therapy in an acute cardioembolic stroke patient. J Stroke Cerebrovasc Dis: Off J Natl Stroke Assoc 23:1747–1749CrossRef
67.
Azizi APS, Cook S, Brugger N (2016) Rivaroxaban dissolves postinfarction left ventricular thrombus. Cardiovasc Med 19:25–27CrossRef
68.
Las Casas AA, Las Casas AA, Borges MAF, Melo-Souza SE (2016) Rivaroxaban for treatment of intraventricular thrombus in Chagas disease. J Cardiol Cases 13:75–77CrossRef
69.
Li Y, Lin J, Peng C (2016) Resolution of massive left atrial appendage thrombi with rivaroxaban before balloon mitral commissurotomy in severe mitral stenosis: a case report and literature review. Medicine (Baltimore) 95:e5577CrossRef
70.
Makrides CA (2016) Resolution of left ventricular postinfarction thrombi in patients undergoing percutaneous coronary intervention using rivaroxaban in addition to dual antiplatelet therapy. BMJ Case Rep 2016:bcr2016217843CrossRefPubMedPubMedCentral
71.
Piotrowski R, Zaborska B, Baran J, Sikora-Frac M, Kulakowski P (2016) Rivaroxaban twice daily for lysis of left atrial appendage thrombus: a potential new therapeutic option. Pol Arch Med Wewn 126:430–431PubMed
72.
Sato T, Oikawa J, Miyagisima K, Yasuno N, Kubo T, Sato A et al (2016) Disappearance of the right ventricular thrombosis dilated cardiomyopathy with rivaroxaban. J Cardiac Fail 22:S233CrossRef
73.
Desai N, Heid J, Leitch A (2017) Early intracardiac thrombus and pulmonary embolus after trauma. BMJ Case Rep 2017:bcr-2017
74.
Nossikoff A, Valerievitch A, Lazarova G, Atanasova A, Donova T (2017) Familial left ventricular non compaction with LV apical thrombus and concominant paroxysmal atrial fibrillation antiocoagulated with NOAC, with thrombus resolution on follow-up. Eur J Heart Fail 19:359
75.
Scarano M, Casale M, Mantini C, Imbalzano E, Consorti C, Clemente D et al (2017) Rivaroxaban as an effective alternative to warfarin in a patient with atrial fibrillation, thrombophilia, and left atrial appendage thrombus: a case report. J Med Case Rep 11:97CrossRefPubMedPubMedCentral
76.
Seecheran R, Seecheran V, Persad S, Seecheran NA (2017) Rivaroxaban as an antithrombotic agent in a patient with ST-segment elevation myocardial infarction and left ventricular thrombus: a case report. J Investig Med High Impact Case Rep 5:2324709617697991PubMedPubMedCentral
77.
Takeuchi H (2017) Rivaroxaban lessens the number of thrombi in the left atrium and right lower pulmonary vein, as illustrated by transoesophageal echocardiography but not 80-MDCT. BMJ Case Rep 2017:bcr2016218036CrossRefPubMed
78.
Sun H, Zhao Q, Wang Y, Lakin R, Feng H, Fan X et al (2018) Daily 10 mg rivaroxaban as a therapy for ventricular thrombus related to left ventricular non-compaction cardiomyopathy: a case report. Medicine (Baltimore) 97:e9670CrossRef
79.
Saito S, Shindo S, Tsudaka S, Uchida K, Shirakawa M, Yoshimura S (2016) Resolving thrombus in the left atrial appendage by edoxaban treatment after acute ischemic stroke: report of 2 cases. J Stroke Cerebrovasc Dis: Off J Natl Stroke Assoc 25:e188–e191CrossRef
80.
Vidal A, Vanerio G (2012) Dabigatran and left atrial appendage thrombus. J Thromb Thrombolysis 34:545–547CrossRefPubMed
81.
Kaku B (2013) Intra-cardiac thrombus resolution after anti-coagulation therapy with dabigatran in a patient with mid-ventricular obstructive hypertrophic cardiomyopathy: a case report. J Med Case Rep 7:238CrossRefPubMedPubMedCentral
82.
83.
Tabata E, Yasaka M, Wakugawa Y, Komori M, Mori K, Tsurusaki Y et al (2013) Increase in the Size of an Intracardiac Thrombus during dabigatran therapy (110 mg b.i.d.) in an acute cardioembolic stroke patient. Cerebrovasc dis Extra 3:78–80CrossRefPubMedPubMedCentral
84.
Vallakati A, Reddy MY, Gibson D, Price M, Feldman T, Knight B et al (2013) Abstract 18610: left atrial thrombus formation after the left atrial appendage exclusion with a novel endoepicardial suture device (LARIAT®). Circulation 128:A18610-A
85.
Briceno DF, Fernando RR, Laing ST (2014) Left atrial appendage thrombus post LARIAT closure device. Heart Rhythm 11:1600–1601CrossRefPubMed
86.
Nagamoto Y, Shiomi T, Matsuura T, Okahara A, Takegami K, Mine D et al (2014) Resolution of a left ventricular thrombus by the thrombolytic action of dabigatran. Heart Vessels 29:560–562CrossRefPubMed
87.
88.
89.
Ohashi N, Okada T, Uchida M, Amioka M, Fujiwara M, Kaseda S (2015) Effects of dabigatran on the resolution of left ventricular thrombus after acute myocardial infarction. Intern Med 54:1761–1763CrossRefPubMed
90.
Ma JF, Fu HX (2016) Apical aneurysm, apical thrombus, ventricular tachycardia and cerebral hemorrhagic infarction in a patient of mid-ventricular non-obstructive hypertrophic cardiomyopathy: a case report. Int J Cardiol 220:828–832CrossRefPubMed
91.
Qazi AH, Wimmer AP, Huber KC, Latus GG, Main ML (2016) Resolution (and late recurrence) of WATCHMAN device-related thrombus following treatment with dabigatran. Echocardiography 33:792–795CrossRefPubMed
92.
Noflatscher MMN, Gassner E-M, Marschang P (2017) Abstracts der Osterreichischen Kardiologischen Gesellschaft zur Jahrestagung 2017. Wiener klinische Wochenschrift 129:1–116
93.
Pescetelli I, Genovesi E, Renda G, Di Renzo E, De Caterina R (2017) Intracardiac thrombi during warfarin anticoagulation—a case report and a brief literature review. Cor et Vasa 59:e277–e281CrossRef
94.
Watanabe T, Shinoda Y, Ikeoka K, Minamisaka T, Fukuoka H, Inui H et al (2017) Dabigatran therapy resulting in the resolution of rivaroxaban-resistant left atrial appendage thrombi in patients with atrial fibrillation. Intern Med 56:1977–1980CrossRefPubMedPubMedCentral
95.
Niedeggen A, Lejczyk J, Kroner S, Stortz C, Reith S, Janssens U (2008) Treatment of intracardiac thrombi with argatroban. Acute Cardiac Care 10:221–226CrossRefPubMed
96.
Keshmiri HMB, Bhat G, Tatooles A, Sayer G (2014) Abstracts of the International Academy of Cardiology Annual Scientific Sessions 2014 19th World Congress on Heart Disease, July 25-28, 2014, Boston, Massachusetts., USA, July 25-28, 2014. Cardiology 128(Suppl 1):1–527
97.
Olbrich K, Wiersbitzky M, Wacke W, Eichler P, Zinke H, Schwock M et al (1998) Atypical heparin-induced thrombocytopenia complicated by intracardiac thrombus, effectively treated with ultra-low-dose rt-PA lysis and recombinant hirudin (Lepirudin). Blood Coagul Fibrinolysis 9:273–277CrossRefPubMed
98.
Hiwarkar P, Stasi R, Sutherland G, Shannon M (2010) Deep vein and intracardiac thrombosis during the post-partum period in Behcet’s disease. Int J Hematol 91:679–686CrossRefPubMed
99.
Margulescu AD, Fraser AG (2012) Resolution of left ventricular thrombus with lepirudin after failed treatment with heparin. Am J Emerg Med 30:1015.e3–1015.e5CrossRef
Metadata
Title
Non-vitamin K antagonist oral anticoagulants for the treatment of intracardiac thrombosis
Authors
Eiman Ghaffarpasand
Maneli D. Tehrani
Jolanta Marszalek
Gerald Chi
Publication date
01-10-2018
Publisher
Springer US
Published in
Journal of Thrombosis and Thrombolysis / Issue 3/2018
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-018-1693-3

Other articles of this Issue 3/2018

Journal of Thrombosis and Thrombolysis 3/2018 Go to the issue

OriginalPaper

The ratio of concentrations of aminocaproic acid and tranexamic acid that prevent plasmin activation of platelets does not provide equivalent inhibition of plasmatic fibrinolysis

OriginalPaper

The effect of cessation of 2nd generation P2Y12 inhibitor therapy on platelet reactivity in patients 1 year after acute myocardial infarction

OriginalPaper

The efficacy and safety of Batroxobin in combination with anticoagulation on cerebral venous sinus thrombosis

BriefCommunication

Residual vein obstruction in patients diagnosed with acute isolated distal deep vein thrombosis associated with active cancer

OriginalPaper

Incidence and outcomes of catheter related thrombosis (CRT) in patients with acute leukemia using a platelet-adjusted low molecular weight heparin regimen

OriginalPaper

microRNAs regulate nitric oxide release from endothelial cells by targeting NOS3
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits